Compare OMCL & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMCL | ARDX |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2000 | 2014 |
| Metric | OMCL | ARDX |
|---|---|---|
| Price | $34.96 | $5.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $53.67 | $15.14 |
| AVG Volume (30 Days) | 517.9K | ★ 3.0M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $787,309,000.00 | $2,607,000.00 |
| Revenue This Year | $6.77 | $37.75 |
| Revenue Next Year | $5.22 | $34.24 |
| P/E Ratio | $857.75 | ★ N/A |
| Revenue Growth | ★ 9.93 | N/A |
| 52 Week Low | $22.66 | $3.50 |
| 52 Week High | $51.84 | $8.40 |
| Indicator | OMCL | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 40.44 |
| Support Level | $33.25 | $5.49 |
| Resistance Level | $37.51 | $6.63 |
| Average True Range (ATR) | 1.33 | 0.23 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 26.83 | 49.01 |
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.